Method for synthesizing amide and / or polypeptide by using temporarily protected amino acids as amine components
By combining temporary protection amino acids and alkynamide condensants, the steps in the polypeptide synthesis process are simplified and racemic avoided, the complicated steps and racemic problems in the prior art are solved, and the efficiency and economicality of polypeptide synthesis are improved.
Patent Information
- Application Number
- PCT/CN2023/098911
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-05
- Filing Date
- 2023-06-07
- Publication Date
- 2024-11-14
AI Technical Summary
In the existing polypeptide synthesis technology, the steps are complicated and inefficient due to the use of amino acid protecting groups, and traditional methods have racemic problems and high costs in the polypeptide synthesis process.
Using temporary protected amino acids as ammonia components, using silanizing reagents to temporarily protect amino and carboxylic groups, and combining them with alkynamide condensation agents to achieve the synthesis of amides and polypeptides, so that the "protection-condensation-deprotection" process is carried out in one pot Perform internally to avoid racemics and reduce chemical use.
Improve the step economy and atomic economy of peptide synthesis, reduce costs, ensure high purity and high yield of the product, and save time and energy consumption.
Smart Images

Figure PCTCN2023098911-FTAPPB-I100001 
Figure PCTCN2023098911-FTAPPB-I100002 
Figure PCTCN2023098911-FTAPPB-I100003
Abstract
Description
A method for synthesizing amides and / or polypeptides using temporarily protected amino acids as ammonia components Technical Field
[0001] The present invention relates to the technical field of organic synthetic chemistry, and in particular to a method for synthesizing amides and / or polypeptides by using temporarily protected amino acids as ammonia components. Background Art
[0002] Peptides and proteins are functionally active molecules formed by the orderly linkage of several naturally occurring α-amino acids through amide bonds (peptide bonds). The formation of amide bonds is the most fundamental chemical reaction in peptide and protein synthesis. The main method for constructing amide bonds is to convert carboxylic acids into reactive intermediates such as acyl chlorides, anhydrides, activated esters, or acyl azides using activating reagents or condensing agents, which then react with another amine to form an amide bond. However, during peptide bond synthesis, since amino acids contain both amino and carboxyl groups, the condensation of two amino acids will produce a mixture of any order. Therefore, the undesirable amino or carboxyl groups must be temporarily protected with appropriate groups before the ligation reaction to ensure directional synthesis. Commonly used amino acid N-terminal protecting groups include fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl, and benzyloxycarbonyl, and C-terminal protecting groups include methyl esters, ethyl esters, tert-butyl esters, and benzyl esters. The introduction of these protecting groups requires additional reagents, and their removal requires a large excess of strong acids, strong bases, palladium catalysts, and other chemical reagents. The use of amino acid protecting groups not only directly leads to extremely low step economy and atom economy in peptide synthesis, increases the cost of peptide synthesis, but also causes serious pollution to the environment.
[0003] In 2016, researchers designed and developed a new alkyneamide condensing agent for the synthesis of amide and peptide bonds. This new condensing agent is easy to prepare, has good stability, a low molecular weight, mild reaction conditions, and requires no additives. Importantly, the α-chiral acid does not undergo racemization during the condensation process, significantly improving product purity and yield. However, during peptide synthesis, this condensing agent still reacts with a carboxyl-protected amino acid as the amino component. After the reaction is complete, the resulting peptide is still protected, and further peptide chain extension requires deprotection. This makes the peptide synthesis process lengthy, time-consuming, labor-intensive, and costly.
[0004] Summary of the Invention
[0005] The present invention aims to at least solve one of the technical problems of the existing polypeptide synthesis technology, which is that the steps are complicated and the efficiency is low due to the use of amino acid protecting groups. To this end, the purpose of the present invention is to provide a method for synthesizing amides and / or polypeptides using temporarily protected amino acids as the amino component. In the present invention, a silanization reagent is used to temporarily protect the carboxyl group of an amino acid or peptide segment whose amino and carboxyl groups are not protected, and then an amide bond or a peptide bond is formed with an α-acyloxy olefin amide derivative of a carboxylic acid. The temporarily protected carboxyl group can be deprotected on-site in the acid treatment step to obtain the target carboxylic acid product, and then the next peptide bond construction cycle is continued. On the other hand, the alkyne amide condensing agent used in the present invention can effectively avoid racemization, that is, the condensing agent or condensation method used in the existing related technology when synthesizing polypeptides using unprotected amino acids can only synthesize dipeptides, and will induce severe racemization when synthesizing tripeptides or polypeptides containing more than three amino acids. The method of the present invention avoids the racemization problem in the process of peptide synthesis. In addition, this "temporary protection" strategy enables the three-step reaction of "protection-condensation-deprotection" to be carried out in one pot, combining the original three steps into one step. This avoids the large excess of chemical reagents, time, manpower and energy consumption required for the pre-preparation of protected amino acids and the removal of these protecting groups, thereby improving the step economy and atom economy of peptide synthesis and significantly reducing the cost of peptide synthesis.
[0006] In order to achieve the above object, the technical solution adopted by the present invention is:
[0007] The first aspect of the present invention provides a method for preparing an amide and / or polypeptide, comprising the following steps:
[0008] After reacting the compound of formula I and the compound of formula II in solvent I, the compound of formula III, a silanization agent, and solvent II are added to carry out a nucleophilic substitution reaction, and the compound of formula IV is obtained after acidification;
[0009] Among them, R 1 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino acid residues lacking a C-terminal carboxyl group, amino acid derivative residues lacking a C-terminal carboxyl group, or polypeptide fragments; R 2 is selected from hydrogen, deuterium, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, silyl or alkylsilyl; R 3 is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R 4 is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino acid residue or polypeptide fragment; EWG is selected from nitro, cyano, sulfonyl, arylsulfonyl, alkanoyl, phosphonyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, silicon, alkylsilyl is optionally unsubstituted or replaced by one or more R 11 Replace; each R 11Independently selected from halogen, hydroxy, carbonyl, and C1-C6 alkyl.
[0010] In some embodiments of the present invention, the aryl group is selected from phenyl, o-tolyl, m-tolyl, p-tolyl, 2,4-xylyl, p-cumenyl, mesityl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthrenyl, 9-phenanthrenyl, 1-acenaphthenyl, 2-azulenyl, 1-pyrenyl, 2-triphenylene, o-biphenyl, m-biphenyl, p-biphenyl, and terphenyl.
[0011] In some embodiments of the present invention, the heteroaryl group is selected from a heterocyclic group having 1 or 2 nitrogen atoms, oxygen atoms or sulfur atoms, and preferably 5 to 10 members, such as, but not limited to, triazolyl, 3-oxadiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-oxazolyl, 3-isoxazolyl, 2-thiazolyl, 3-isothiazolyl, 2-imidazolyl, 3-pyrazolyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl, 1-isoquinolyl, 2-quinoxalinyl, 2-benzofuranyl, 2-benzothienyl, N-indolyl, and N-carbazolyl.
[0012] In some embodiments of the present invention, R 1 In the embodiment, the amino acid residue with a missing C-terminal carboxyl group or the amino acid derivative residue with a missing C-terminal carboxyl group refers to the remaining portion of the amino acid or amino acid derivative after the C-terminal carboxyl group is missing; preferably, the amino acid residue with a missing C-terminal carboxyl group includes at least one of an α-amino acid residue with a missing C-terminal carboxyl group, a β-amino acid residue with a missing C-terminal carboxyl group or a γ-amino acid residue with a missing C-terminal carboxyl group; preferably, the amino acid derivative residue with a missing C-terminal carboxyl group includes an amino acid residue with a missing C-terminal carboxyl group protected by a C-terminal amino group, such as an amino acid residue with a missing C-terminal carboxyl group protected by an N-alkoxycarbonyl group and / or an N-acyl group; preferably, generally To represent α-amino acid, then R 1 wherein the amino acid residue with the C-terminal carboxyl group missing is It can be in R or S configuration; specifically, the amino acid residue with the C-terminal carboxyl group missing is selected from Preferably, the C-terminal carboxyl group-deficient amino acid derivative residue is selected from the C-terminal carboxyl group-deficient amino acid residues whose C-terminal amino group is protected by N-alkoxycarbonyl and / or N-acyl groups among the above-mentioned C-terminal carboxyl group-deficient amino acid residues.
[0013] In some embodiments of the present invention, when solvent II is different from solvent I, the method for preparing the amide and / or polypeptide further comprises removing the solvent I after the reaction and then performing the nucleophilic substitution reaction.
[0014] In some embodiments of the present invention, the acidifying acidulant comprises an organic acid and / or an inorganic acid.
[0015] The term "acidifier" may refer to any material that lowers the pH of a solution by dissolving in water. In some embodiments, the acidifier may be an inorganic acid and / or organic acid that can lower the pH of a solution to 5 or lower (e.g., pH ≤ 4, pH ≤ 3, pH ≤ 2, pH ≤ 1) by dissolving in water.
[0016] Inorganic acid can include hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sulfonic acid, sulfamic acid, sulfuric acid, nitric acid or any combination thereof. However, embodiments are not limited thereto. Organic acid can include citric acid, lactic acid, tartaric acid, fumaric acid, trifluoroacetic acid, phthalic acid, acetic acid, oxalic acid, malonic acid, adipic acid, phytic acid, succinic acid, glutaric acid, maleic acid, malic acid, mandelic acid, ascorbic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, salicylic acid, capric acid, caproic acid, sad, lauric acid, arachidic acid, erucic acid, linoleic acid, linolenic acid, oleic acid, palmitic acid, myristic acid, edisilic acid (edisilic acid), stearic acid or any combination thereof. However, embodiments are not limited thereto.
[0017] The second aspect of the present invention provides another method for preparing an amide and / or polypeptide, comprising the following steps:
[0018] Dissolving the compound of formula V, the compound of formula III, and a silanization agent in solvent II to carry out a nucleophilic substitution reaction, and then acidifying to obtain a compound of formula IV;
[0019] Among them, R 1 、R 2 、R 3 、R 4 The definition of is as mentioned above.
[0020] In the present invention, since the compound of formula III (a compound containing both amino and carboxyl groups) exists as a compound of formula III-A (an intramolecular zwitterion) under neutral conditions, the amino group in compound III-A is not nucleophilic under normal conditions and is difficult to undergo condensation reactions. A silanization agent can be used to temporarily protect the carboxyl group of compound III-A to form a compound of formula III-B (silicon ester compound), while simultaneously freeing the amino group. This can then undergo a nucleophilic substitution reaction with compound V to form an amide bond / peptide bond, producing an amide or polypeptide compound of formula IV, while also forming a byproduct of formula VI. The reaction mechanism is as follows:
[0021] In some embodiments of the present invention, the silanization agent includes at least one of N-trimethylsilylacetamide, N-methyl-N-trimethylsilylacetamide, N-trimethylsilylpyrrolidone, N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide, N,O-bis(tert-butyldimethylsilyl)acetamide, N,O-bistrimethylsilylacetamide, N,O-bis(trimethylsilyl)trifluoroacetamide, N-methyl-N-(trimethylsilyl)trifluoroacetamide, hexamethyldisilazane, trimethylsilylimidazole, dimethyldichlorosilane, trimethylchlorosilane and tert-butyldimethylchlorosilane.
[0022] In some embodiments of the present invention, the molar ratio of the silanization agent to the compound of formula III is (0.5-20):1; preferably (1-15):1; more preferably (2-10):1.
[0023] In some embodiments of the present invention, the compound of formula III is an organic compound having both an amino group and a carboxyl group; preferably, the compound of formula III includes any one of an amino acid compound, a polypeptide compound having both free amino and carboxyl groups, or other compounds having both amino and carboxyl groups; further preferably, the compound of formula III includes any one of an α-amino acid, a β-amino acid, a γ-amino acid, or a polypeptide compound having both unprotected amino and carboxyl groups; even more preferably, the compound of formula II includes any one of glycine, alanine, leucine, isoleucine, proline, valine, phenylalanine, tyrosine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, asparagine, glutamine, tryptophan, histidine, lysine, arginine, citrulline, or derivatives of the above amino acids. It should be understood that the twenty-one amino acids included in the compound of formula III can all be natural α-amino acids in their L-configuration and / or their corresponding D-configuration α-amino acids.
[0024] In some embodiments of the present invention, the solvent II includes at least one of acetonitrile, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, dioxane, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, toluene, m-xylene, dichloromethane, 1,2-dichloroethane or chloroform.
[0025] In some embodiments of the present invention, the temperature of the nucleophilic substitution reaction is -20°C to 150°C; preferably 0°C to 90°C, and more preferably 5°C to 50°C.
[0026] In some embodiments of the present invention, the method for preparing the amide and / or polypeptide comprises the following steps: dissolving the compound of formula III and a silanization agent in a solvent II, adding the compound of formula V to carry out a nucleophilic substitution reaction, and acidifying to obtain the compound of formula IV.
[0027] In some embodiments of the present invention, the method for preparing the amide and / or polypeptide comprises the following steps: dissolving the compound of formula III and a silanization agent in a solvent II by stirring for 5 minutes to 24 hours, then adding the compound of formula V to carry out a nucleophilic substitution reaction, and obtaining the compound of formula IV after acidification.
[0028] In some embodiments of the present invention, the method for preparing the amide and / or polypeptide further comprises a step of purifying the product after the nucleophilic substitution reaction, wherein the purification comprises at least one of extraction, recrystallization or column chromatography.
[0029] In some embodiments of the present invention, the method for preparing the compound of formula V comprises the following steps:
[0030] The compound of formula I and the compound of formula II are dissolved in solvent I and stirred to react to obtain the compound of formula V;
[0031] Wherein, the definitions of R1, R2, R3, and EWG are as described above.
[0032] In some embodiments of the present invention, the solvent I comprises at least one of dichloromethane, chloroform, 1,2-dichloroethane, ether, toluene, acetonitrile, methanol or ethanol.
[0033] In some embodiments of the present invention, the compound of formula I is a carboxylic acid compound; preferably, the compound of formula I includes at least one of a fatty acid, an aromatic acid, a heterocyclic acid, an alkyne acid, an alkenoic acid, an N-acyl amino acid, an N-alkoxycarbonyl amino acid or a polypeptide carboxylic acid; further preferably, the compound of formula I includes at least one of an N-benzyloxycarbonyl amino acid, an N-tert-butyloxycarbonyl amino acid, an N-fluorenylmethoxycarbonyl amino acid, an N-acetyl amino acid or a polypeptide carboxylic acid.
[0034] In some embodiments of the present invention, the molar ratio of the compound of formula I to the compound of formula II is 1:(1-5); preferably 1:(1.1-4); more preferably 1:(1.2-3).
[0035] In some embodiments of the present invention, the stirring reaction temperature is -20°C to 90°C; preferably 0°C to 50°C.
[0036] In some embodiments of the present invention, the method for preparing the amide and / or polypeptide comprises the following steps:
[0037] S1: dissolving the compound of formula I and the compound of formula II in solvent I and stirring to react to obtain the compound of formula V;
[0038] S2: dissolving the compound of formula V, the compound of formula III, and a silanization agent in solvent II to carry out a nucleophilic substitution reaction, and then acidifying to obtain a compound of formula IV;
[0039] Among them, R 1 、R 2 、R 3 、R 4 , the definition of EWG is as described above.
[0040] According to a third aspect of the present invention, a method for preparing the amide and / or polypeptide and its application in preparing polypeptides are proposed.
[0041] The beneficial effects of the present invention are:
[0042] In the preparation method of amides and / or polypeptides of the present invention, an alkynamide compound is used as a condensation reagent, a low-cost unprotected amino acid is used as a raw material, and a silanization agent is used to temporarily protect the amino acid for condensation reaction, so that "protection-condensation-deprotection" is carried out in one pot, and the three-step reaction is combined into one step. After the construction of the peptide bond is achieved, a simple acid treatment can obtain the target polypeptide carboxylic acid, which is directly used for the condensation of the next amino acid. At the same time, based on the characteristics of the alkynamide condensing agent, the method can also completely avoid the generation of racemic by-products, ensuring the yield and purity of the product. The method saves a large amount of reagents and solvents used in the "protecting groups on amino acids" and "product deprotection" in traditional methods, reduces the generation of a large amount of chemical waste, and saves time, human resources and energy consumption, significantly reduces the cost of polypeptide synthesis, improves the atom economy and step economy of polypeptide synthesis, efficiently achieves energy conservation and emission reduction, greatly improves the efficiency of polypeptide synthesis, and has broad industrial application prospects. DETAILED DESCRIPTION
[0043] The present invention is further described in detail below using specific examples. Unless otherwise specified, the raw materials, reagents, and apparatus used in the examples and comparative examples are available from conventional commercial sources or by conventional methods. Unless otherwise specified, all experimental or testing methods are conventional in the art.
[0044] Example 1
[0045] This example prepared a polypeptide of formula 1, and the specific process was as follows:
[0046] Boc-Val-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Phe-OH (1 mmol), N-trimethylsilyl acetamide (1 mmol), and 3 mL of N,N-dimethylformamide for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 2 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr > 99:1 and a yield of 94%.
[0047] Product NMR experimental data, mass spectrometry experimental data:
[0048] 1 H NMR (400MHz, DMSO) δ8.04(d,J=7.8Hz,1H),7.30–7.16(m,5H),6.54(d,J=9.2Hz,1H),4.47(dd,J=13.3,8.3Hz,1H),3.78(t,J =8.0Hz,1H),3.06(dd,J=13.9,5.0Hz,1H),2.90(dd,J=13.9,9.1Hz,1H),1.97–1.77(m,1H),1.38(s,9H),0.83–0.71(m,6H).
[0049] 13 C NMR (100MHz, DMSO) δ = 172.8, 171.3, 155.2, 137.4, 129.1, 128.1, 126.4, 78.0, 59.7, 53.2, 36.8, 30.5, 28.2, 19.1, 18.1.
[0050] HRMS(ESI)m / z calcd.for C 19 H 29 N2O5[M+H] + :365.2071,found:365.2077
[0051] Example 2
[0052] This example prepared a polypeptide of formula 2, and the specific process was as follows:
[0053] Cbz-Pro-OH (0.5 mmol) and N-methyl-N-methylsulfonylacetylamine (0.55 mmol) were dissolved in 5 mL of dichloroethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Phe-OH (1 mmol), N,O-bistrimethylsilylacetamide (1 mmol), and 3 mL of dichloroethane for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 2 with 2M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The product was separated by column chromatography to obtain the pure product as a white solid with a dr ratio of >99:1 in a 93% yield.
[0054] Product NMR experimental data, mass spectrometry experimental data:
[0055] 1 H NMR (400MHz, DMSO-d6) δ8.38–8.03(m,1H),7.42–7.11(m,10H),5.12–5.02(m,1H),5.01–4.82(m,1H),4.53–4.40(m,1H) ,4.23(d,J=8.1Hz,1H),3.40–3.29(m,2H),3.12–3.00(m,1H),2.99–2.84(m,2H),2.13–1.96(m,1H),1.80–1.59(m,3H).
[0056] 13C NMR (100MHz, DMSO) δ = 172.9, 172.8, 172.1, 171.8, 154.2, 153.8, 137.6, 137.5, 137.1, 129.2, 129.0, 128.4, 128.2, 128.1 ,128.1,127.8,127.5,127.0,126.4,126.3,65.9,65.7,59.7,59.3,53.5,53.1,47.1,46.5,36.6,31.0,29.7,23.7,22.8.
[0057] HRMS(ESI)m / z calcd.for C 22 H 25 N2O5[M+H] + :397.1758,found:397.1764
[0058] Example 3
[0059] This example prepared a polypeptide of formula 3, and the specific process was as follows:
[0060] Cbz-Phe-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.5 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Phe-OH (1 mmol), N,O-bistrimethylsilyl acetamide (1 mmol), and 3 mL of N,N-dimethylformamide for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 2 with 2M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The product was separated by column chromatography to obtain the pure product as a white solid with a dr ratio >99:1 in a 95% yield.
[0061] Product NMR experimental data, mass spectrometry experimental data:
[0062] 1H NMR (400MHz, DMSO-d6) δ8.28(d,J=7.7Hz,1H),7.46(d,J=8.7Hz,1H),7.37–7.17(m,15H),4.95(s,2H),4.52(d d,J=13.1,7.7Hz,1H),4.37–4.28(m,1H),3.12(dd,J=13.8,5.0Hz,1H),3.03–2.90(m,2H),2.78–2.67(m,1H).
[0063] 13 C NMR(100MHz,DMSO-d6)δ173.2,172.0,156.2,138.5,137.8,137.5,129.7,12 8.7,128.7,128.5,128.1,127.9,126.9,126.7,65.7,56.5,53.9,37.9,37.2.
[0064] HRMS(ESI)m / z calcd.for C 26 H 27 N2O6[M+H] + :447.1914,found:447.1919
[0065] Example 4
[0066] This example prepared a polypeptide of formula 4, and the specific process was as follows:
[0067] Cbz-Thr-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetyl amine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Phe-OH (1 mmol), hexamethyldisilazane (1 mmol), and 3 mL of acetonitrile for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 2 with 2M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr > 99:1 and a yield of 95%.
[0068] Product NMR experimental data, mass spectrometry experimental data:
[0069] 1H NMR (400MHz, DMSO-d6) δ8.06(d,J=7.7Hz,1H),7.41–7.17(m,10H),6.95(d,J=8.7Hz,1H),5.05(s,2H),4.48(q,J=7.3Hz,1H),3. 96(dd,J=8.2,5.2Hz,1H),3.88–3.76(m,1H),3.05(dd,J=13.7,5.0Hz,1H),2.93(dd,J=13.6,8.1Hz,1H),1.01(d,J=6.1Hz,3H).
[0070] 13 C NMR (100MHz, DMSO-d6) δ172.6,170.0,156.0,137.3,137.0,129.2,128.3,128.1,127.8,127.7,126.4,66.8,65.5,60.5,53.3,36.9,19.6.
[0071] HRMS(ESI)m / z calcd.for C 21 H 24 N2NaO6[M+Na] + :423.1527,found:423.1524
[0072] Example 5
[0073] This example prepared a polypeptide of formula 5, and the specific process was as follows:
[0074] Boc-Met-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.5 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-mixed mixture of H-Phe-OH (1 mmol), trimethylsilyl imidazole (1 mmol), and 3 mL of acetonitrile for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The product was separated by column chromatography to obtain the pure product as a white solid with a dr > 99:1 and a yield of 97%.
[0075] Product NMR experimental data, mass spectrometry experimental data:
[0076] 1H NMR (400MHz, DMSO-d6) δ7.97(d,J=7.8Hz,1H),7.34–7.16(m,5H),6.91(d,J=8.2Hz,1H),4.46(q,J=8.0Hz,1H),4.01(q,J=7.9Hz, 1H),3.07(dd,J=13.8,4.9Hz,1H),2.92(dd,J=13.9,8.7Hz,1H),2.45–2.29(m,2H),2.01(s,3H),1.85–1.64(m,2H),1.37(s,9H).
[0077] 13 C NMR (100MHz, DMSO-d6) δ172.8,171.6,155.2,137.3,129.2,128.1,126.4,78.2,53.6,53.2,36.7,31.9,29.6,28.2,14.6.
[0078] HRMS(ESI)m / z calcd.for C 19 H 28 N2NaO5S[M+Na] + :419.1611,found:419.1609
[0079] Example 6
[0080] This example prepared a polypeptide of formula 6, and the specific process was as follows:
[0081] Take Boc-Glu(O t Bu)-OH (0.5 mmol) and N-methyl-N-methylsulfonylacetylamine (0.5 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Phe-OH (1 mmol), N,O-bis(trimethylsilyl)trifluoroacetamide (1 mmol), and 3 mL of dimethyl sulfoxide for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, washed once with water and once with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The mixture was separated by column chromatography to obtain the pure product as a white solid with a dr > 99:1 and a yield of 94%.
[0082] Product NMR experimental data, mass spectrometry experimental data:
[0083] 1H NMR(400MHz, DMSO-d6)δ7.95(d,J=7.9Hz,1H),7.36–7.10(m,5H),6.82(d,J=8.3Hz,1H),4.52–4.40(m,1H),4.01–3.85(m,1H),3.07(dd, J=13.8,4.8Hz,1H),2.92(dd,J=13.9,8.8Hz,1H),2.16(t,J=7.6Hz,2H),1.85–1.72(m,1H),1.70–1.58(m,1H),1.40(s,9H),1.37(s,9H).
[0084] 13 C NMR (100MHz, DMSO-d6) δ172.7,171.7,171.5,155.1,137.3,129.2,128.1,126.4,79.5,78.2,53.5,53.2,36.7,31.2,28.1,27.8,27.4.
[0085] HRMS(ESI)m / z calcd.for C 23 H 34 N2O7[M+H] + :451.2439,found:451.2445
[0086] Example 7
[0087] This example prepared a polypeptide of formula 7, and the specific process was as follows:
[0088] Cbz-Ala-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of chloroform and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Thr-OH (1 mmol), N,O-bistrimethylsilyl acetamide (2 mmol), and 3 mL of chloroform. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 2 with 2M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the mixture was recrystallized from ethyl acetate and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 92%.
[0089] Product NMR experimental data, mass spectrometry experimental data:
[0090] 1H NMR(400MHz,DMSO-d6)δ7.67(d,J=8.6Hz,1H),7.53(d,J=7.7Hz,1H),7.39–7.26(m ,5H),5.03(s,2H),4.25–4.14(m,3H),1.24(d,J=7.1Hz,3H),1.06(d,J=6.1Hz,3H).
[0091] 13 C NMR (100MHz, DMSO-d6) δ173.0,172.2,155.8,137.1,128.5,127.9,127.8,66.5,65.5,57.5,50.2,20.4,18.2.
[0092] HRMS(ESI)m / z calcd.for C 15 H 20 N2O6[M+Na] + :347.1214,found:347.1221
[0093] Example 8
[0094] This example prepared a polypeptide of formula 8, and the specific process was as follows:
[0095] Cbz-Ala-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Gln-OH (1 mmol), N,O-bistrimethylsilylacetamide (2 mmol), and 3 mL of N,N-dimethylacetamide for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 1 with 2 M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio > 99:1 and a yield of 95%.
[0096] Product NMR experimental data, mass spectrometry experimental data:
[0097] 1H NMR(400MHz, DMSO-d6)δ8.13(d,J=7.6Hz,1H),7.59–7.12(m,7H),6.79(s,1H),5.09–4.95(m,2H), 4.22–4.05(m,2H),2.22–2.07(m,2H),2.01–1.91(m,1H),1.86–1.73(m,1H),1.22(d,J=7.1Hz,3H).
[0098] 13 C NMR (100MHz, DMSO-d6) δ173.6,173.3,172.7,155.7,137.1,128.4,127.8,127.8,65.4,51.6,49.9,31.4,27.0,18.2.
[0099] HRMS(ESI)m / z calcd.for C 16 H 21 N3NaO6[M+Na] + :374.1323,found:374.1321
[0100] Example 9
[0101] This example prepared a polypeptide of formula 9, and the specific process was as follows:
[0102] Cbz-Ala-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a system containing a pre-stirred mixture of H-Trp-OH (1 mmol), hexamethyldisilazane (1 mmol), and 3 mL of N-methylpyrrolidone for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 1 with 2M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was separated by column chromatography to obtain the pure product as a light yellow solid with a dr > 99:1 and a yield of 95%.
[0103] Product NMR experimental data, mass spectrometry experimental data:
[0104] 1H NMR (400MHz, DMSO-d6) δ10.89(s,1H),8.12–8.03(m,1H),7.57(t,J=6.0Hz,1H),7.44(dd,J=8.1,4.1Hz,1H),7.34(d,J=15.7Hz,8H),7.20(s,1H),7 .07(s,1H),6.98(s,1H),5.13–4.94(m,3H),4.54(s,1H),4.15(q,J=5.8, 4.9Hz,2H),3.22(d,J=14.3Hz,2H),3.17–3.05(m,2H),1.26–1.19(m,7H).
[0105] 13 C NMR(100MHz,DMSO-d6)δ173.3,172.6,155.7,137.1,136.1,128.4,127.8,127.8 ,127.4,123.8,121.0,118.4,118.3,111.4,109.7,65.5,53.0,50.0,27.1,18.3.
[0106] HRMS(ESI)m / z calcd.for C 22 H 23 N3NaO5[M+Na] + :432.1530,found:432.1530
[0107] Example 10
[0108] This example prepared a polypeptide of formula 10, and the specific process was as follows:
[0109] Fmoc-Ala-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 3 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-mixed mixture of H-Phe-OH (1 mmol), N-methyl-N-trimethylsilyl acetamide (1 mmol), and 3 mL of dichloromethane for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH = 1 with 2M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The product was separated by column chromatography to obtain the pure product as a white solid with a dr > 99:1 and a yield of 93%.
[0110] Product NMR experimental data, mass spectrometry experimental data:
[0111] 1 H NMR (400MHz, DMSO-d6) δ8.02(d,J=7.5Hz,1H),7.89(d,J=7.5Hz,2H),7.74(d,J=6.8H z,1H),7.48(d,J=7.7Hz,1H),7.42(t,J=7.4Hz,2H),7.33(t,J=7.3Hz,2H),7.27–7.16 (m,4H),4.50–4.39(m,1H),4.26(d,J=6.1Hz,1H),4.24–4.18(m,1H),4.12–4.06(m,1 H), 3.07 (dd, J=13.7, 4.8Hz, 1H), 2.93 (dd, J=13.7, 8.4Hz, 1H), 1.20 (d, J=7.1Hz, 3H).
[0112] 13 C NMR(100MHz,DMSO-d6)δ172.8,172.4,155.6,143.9,143.8,140.7,137.4,129.2 ,128.1,127.6,127.1,126.3,125.3,120.1,65.7,53.5,49.9,46.6,36.7,18.2.
[0113] HRMS(ESI)m / z calcd.for C 22 H 23 N3NaO5[M+Na] + :432.1530,found:432.1530
[0114] Example 11
[0115] This example prepared a polypeptide of formula 11, and the specific process was as follows:
[0116] Boc-Phe-Ala-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetyl amine (0.5 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction process was monitored by TLC. After the raw acid was completely consumed, the mixture was transferred to a pre-mixed mixture of H-Ser(O tThe reaction was carried out in a system of 1,2-dichloroethane (5 mL) of 1,2-dichloroethane (Bu)-OH (1 mmol), N-trimethylsilyl pyrrolidone (1 mmol), and 1,2-dichloroethane (5 mL). The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added, and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with dichloromethane, and the organic phases were combined, washed once with water and once with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The product was recrystallized from diethyl ether, and the solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 94%.
[0117] Product NMR experimental data, mass spectrometry experimental data:
[0118] 1 H NMR (400MHz, DMSO-d6) δ8.04(d,J=7.4Hz,1H),7.94(d,J=7.9Hz,1H),7.32–7.15(m,5H),6.94(d,J=8.5Hz,1H),4.49–4.41(m,1H),4.40–4.30(m,1 H),4.22–4.11(m,1H),3.69–3.60(m,1H),3.54–3.48(m,1H),3.05–2.94( m,1H),2.78–2.65(m,1H),1.29(s,9H),1.24(d,J=6.8Hz,3H),1.11(s,9H)
[0119] 13 C NMR (100MHz, DMSO-d6) δ172.1,171.4,171.3,155.2,138.2,129.2,127.9,126.1,78.0,72.8,61.5,55.6,52.8,47.8,37.4,28.1,27.1,18.4.
[0120] HRMS(ESI)m / z calcd.for C 24 H 38 N3O7[M+H] + :480.2704,found:480.2710
[0121] Example 12
[0122] This example prepared a polypeptide of formula 12, and the specific process was as follows:
[0123] Cbz-Ala-Leu-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.5 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Phe-OH (1 mmol), N,O-bistrimethylsilyl acetamide (1 mmol), and 5 mL of dichloromethane for reaction. The reaction progress was monitored by TLC. After the reaction, 15 mL of water was added and the mixture was acidified to pH 1 with 2M hydrochloric acid. The aqueous phase was extracted twice with dichloromethane. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 91%.
[0124] Product NMR experimental data, mass spectrometry experimental data:
[0125] 1 H NMR (400MHz, DMSO-d6) δ8.04(d,J=7.6Hz,1H),7.86(d,J=8.3Hz,1H),7.43(d,J=7 .6Hz,1H),7.37–7.17(m,10H),5.02(s,2H),4.47–4.41(m,1H),4.36–4.30(m,1H) ,4.10–4.04(m,1H),3.07(dd,J=13.9,5.2Hz,1H),2.93(dd,J=13.8,8.5Hz,1H),1 .67–1.50(m,1H),1.43(d,J=6.7Hz,1H),1.17(d,J=7.0Hz,3H),0.90–0.76(m,6H).
[0126] 13 C NMR(100MHz,DMSO-d6)δ1172.8,172.2,171.9,155.7,137.5,137.1,129.2,128.4,12 8.2,127.8,127.8,126.4,65.4,53.4,51.0,50.1,41.1,36.7,24.1,23.1,21.8,18.2.
[0127] HRMS(ESI)m / z calcd.forC 26 H 34 N3O6[M+H] + :484.2442,found:284.2448
[0128] Example 13
[0129] This example prepared a polypeptide of formula 13, and the specific process was as follows:
[0130] Cbz-Ala-Ala-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Gln(Trt)-OH (1 mmol), N,O-bis(trimethylsilyl)acetamide (2 mmol), and 5 mL of dichloromethane for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted once with ethyl acetate, washed twice with water, and the organic phase was washed once with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The mixture was recrystallized from dichloromethane and diethyl ether, and the solid was collected by filtration to obtain the pure product as a pale yellow solid with a dr ratio of >99:1 and a yield of 95%.
[0131] Product NMR experimental data, mass spectrometry experimental data:
[0132] 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),8.05(d,J=8.2Hz,1H),7.93(t,J=6.5Hz,1H),7.44(t,J=5.9Hz,1H),7.38–7.14(m,22H),5.06–4.97(m ,2H),4.37–4.29(m,1H),4.22–4.15(m,1H),4.11–4.05(m,1H),2.41– 2.29(m,2H),1.99–1.88(m,1H),1.79–1.69(m,1H),1.26–1.16(m,6H).
[0133] 13 C NMR(100MHz,DMSO-d6)δ173.3,172.1,172.0,171.2,155.7,144.9,137.0,128.5,128 .3,127.8,127.7,127.4,126.3,69.3,65.4,51.6,50.0,47.9,32.6,27.3,18.3,18.1.
[0134] HRMS(ESI)m / z calcd.for C 38 H 40 N4NaO7[M+Na] + :687.2789,found:687.2874
[0135] Example 14
[0136] This example prepared a polypeptide of formula 14, and the specific process was as follows:
[0137] Boc-Ala-Phe-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Tyr(OtBu)-OH (1 mmol), N,O-bistrimethylsilylacetamide (2 mmol), and 5 mL of dichloromethane for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted once with ethyl acetate, washed twice with water, and the organic phase was washed once with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The mixture was recrystallized from diethyl ether and petroleum ether, and the solid was collected by filtration to obtain the pure product as a pale yellow solid with a dr ratio >99:1 and a yield of 91%.
[0138] Product NMR experimental data, mass spectrometry experimental data:
[0139] 1 H NMR (400MHz, DMSO-d6) δ8.35–8.22(m,1H),7.80–7.66(m,1H),7.27–7.11(m,7H),6.94–6.78(m,3H),4.64–4.52(m,1H),4.48–4.37( m,1H),3.99–3.82(m,1H),3.07–2.96(m,2H),2.93–2.84(m,1H),2.82–2.69(m,1H),1.36(s,9H),1.26(s,9H),1.06(d,J=6.6Hz,3H).
[0140] 13 C NMR(100MHz,DMSO-d6)δ172.64,172.15,170.76,154.86,153.59,137.44,131.81,129.53,129 .28,127.86,126.12,123.34,78.09,77.58,53.41,53.20,49.81,37.67,36.04,28.53,28.14, 18.14.
[0141] HRMS(ESI)m / z calcd.for C 30 H 41N3NaO7[M+Na] + :578.2837,found:578.2840.
[0142] Example 15
[0143] This example prepared a polypeptide of formula 15, and the specific process was as follows:
[0144] Cbz-Ala-Phe-Met-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-mixed mixture of H-Glu(OtBu)-OH (1 mmol), hexamethyldisilazane (1 mmol), and 3 mL of dichloromethane for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 92%.
[0145] Product NMR experimental data, mass spectrometry experimental data:
[0146] 1 H NMR (400MHz, DMSO-d6) δ8.13(d,J=7.5Hz,1H),8.07(d,J=7.4Hz,1H),7.93(d,J=7.3Hz,1H),7.43(d,J= 7.1Hz,1H),7.40–7.28(m,5H),7.25–7.15(m,5H),5.09–4.93(m,2H),4.60–4.49(m,1H),4.44–4.36(m, 1H),4.28–4.20(m,1H),4.05–3.98(m,1H),3.09–3.00(m,1H),2.90–2.80(m,1H),2.49–2.40(m,2H),2. 33–2.23(m,2H),2.03(s,3H),2.02–1.89(m,2H),1.88–1.74(m,2H),1.39(s,9H),1.14(d,J=7.0Hz,3H)
[0147] 13C NMR(100MHz,DMSO-d6)δ173.0,172.4,171.5,170.9,170.7,155.7,137.6,136.9,129.3,128.3,127.9,1 27.8,127.7,126.2,79.8,65.5,53.6,51.7,51.1,50.3,37.2,32.2,31.2,29.3,27.7,26.3,18.0,14.6.
[0148] HRMS(ESI)m / z calcd.for C 34 H 47 N4O9S[M+H] + :687.3058,found:687.3065
[0149] Example 16
[0150] This example prepared a polypeptide of formula 16, and the specific process was as follows:
[0151] Cbz-Phe-Gly-Ala-Glu(tBu)-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-mixed mixture of H-Phe-OH (1 mmol), N-methyl-N-trimethylsilyl acetamide (2 mmol), and 5 mL of acetonitrile for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 90%.
[0152] Product NMR experimental data, mass spectrometry experimental data:
[0153] 1H NMR (400MHz, DMSO-d6) δ8.43–8.25(m,1H),8.12–7.89(m,3H),7.57(d,J=7.1Hz,1H ),7.37–7.13(m,15H),5.04–4.87(m,2H),4.52–4.42(m,1H),4.40–4.24(m,3H),3. 84–3.71(m,2H),3.12–3.01(m,2H),2.99–2.89(m,1H),2.84–2.72(m,1H),2.32–2. 13(m,2H),1.96–1.83(m,1H),1.81–1.66(m,1H),1.39(s,9H),1.20(d,J=6.2Hz,3H)
[0154] 13 C NMR(100MHz,DMSO-d6)δ172.7,171.9,171.9,171.8,170.9,168.4,156.0,138.1,137.3,137.0,129.2,129.1,128.3,1 28.2,128.0,127.7,127.4,126.4,126.2,79.6,65.3,56.3,53.4,51.6,48.1,42.1,37.3,36.6,31.2,27.8,27.5,18.2.
[0155] HRMS(ESI)m / z calcd.for C 40 H 50 N5O 10 [M+H] + :760.3552,found:760.3557
[0156] Example 17
[0157] This example prepared a polypeptide of formula 17, and the specific process was as follows:
[0158] Boc-β-Ala-Trp-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Met-OH (1 mmol), N,O-bis(trimethylsilyl)trifluoroacetamide (1 mmol), and 3 mL of acetonitrile for reaction. The reaction progress was monitored by TLC. After the reaction, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 94%.
[0159] Product NMR experimental data, mass spectrometry experimental data:
[0160] 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.28(d,J=7.7Hz,1H),8.06(d,J=8.1Hz,1H),7.62(d,J=7. 8Hz,1H),7.33(d,J=8.0Hz,1H),7.15(s,1H),7.06(t,J=7.4Hz,1H),6.98(t,J=7.4Hz,1H),6.65(t ,J=5.2Hz,1H),4.66–4.53(m,1H),4.41–4.29(m,1H),3.18–3.01(m,3H),2.96–2.85(m,1H),2.52 –2.41(m,2H),2.29–2.14(m,2H),2.04(s,3H),2.02–1.95(m,1H),1.95–1.84(m,1H),1.36(s,9H).
[0161] 13 C NMR(100MHz,DMSO-d6)δ173.2,171.9,170.3,155.5,136.1,127.4,123.6,120.9,118 .5,118.2,111.3,110.2,77.6,53.2,51.0,36.7,35.7,30.8,29.7,28.3,27.7,14.7.
[0162] HRMS(ESI)m / z calcd.for C 24 H 35 N4O6S[M+H]+ :507.2272,found:507.2278
[0163] Example 18
[0164] This example prepared a polypeptide of formula 18, and the specific process was as follows:
[0165] Cbz-Tyr(tBu)-Gly-Gly-Phe-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the dichloromethane was removed by distillation under reduced pressure, and the mixture was transferred to a pre-stirred mixture of H-Leu-OH (1 mmol), N,O-bistrimethylsilylacetamide (1 mmol), and 5 mL of N,N-dimethylformamide for reaction. The reaction progress was monitored by TLC. After the reaction, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 90%.
[0166] Product NMR experimental data, mass spectrometry experimental data:
[0167] 1 H NMR (400MHz, DMSO-d6) δ8.35–8.20(m,2H),8.09–7.93(m,2H),7.60–7.46(m,1H),7.38–7.14(m,12H),6.85(d,J=7.9Hz,2H),5.04 –4.84(m,2H),4.70–4.54(m,1H),4.36–4.20(m,2H),3.82–3.70(m,3H),3.69–3.62(m,1H),3.12–2.97(m,2H),2.84–2.65(m,2H), 1.74–1.49(m,3H),1.26(s,9H),0.97–0.80(m,6H).
[0168] 13C NMR(100MHz,DMSO-d6)δ173.9,171.9,171.1,168.9,168.3,155.9,153.5,137.8,137.0,132.7,129.7,129.3,128.3, 128.0,127.7,127.5,126.2,123.3,77.6,65.3,56.3,53.6,50.4,42.1,41.8,40.0,37.7,36.8,28.6,24.3,22.8,21.4
[0169] HRMS(ESI)m / z calcd.for C 40 H 52 N5O9[M+H] + :746.3760,found:746.3766
[0170] Example 19
[0171] This example prepared a polypeptide of formula 19, and the specific process was as follows:
[0172] Cbz-Tyr(tBu)-Gly-Gly-OH (0.5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (0.55 mmol) were dissolved in 5 mL of dichloroethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Phe-Met-OH (1 mmol), N-trimethylsilyl pyrrolidone (1 mmol), and 5 mL of dichloroethane for reaction. The reaction progress was monitored by TLC. After the reaction was completed, 15 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain the pure product as a white solid with a dr ratio of >99:1 and a yield of 93%.
[0173] Product NMR experimental data, mass spectrometry experimental data:
[0174] 1H NMR(400MHz,DMSO-d6)δ8.40–8.20(m,2H),8.16–8.07(m,1H),8.07–7.97(m,1H), 7.54(d,J=8.1Hz,1H),7.35–7.15(m,12H),6.86(d,J=7.6Hz,2H),4.94(s,2H),4. 64–4.52(m,1H),4.38–4.24(m,2H),3.79–3.63(m,4H),3.11–2.97(m,2H),2.86–2 .69(m,2H),2.51–2.41(m,2H),2.08–1.96(m,4H),1.94–1.86(m,1H),1.26(s,9H).
[0175] 13 C NMR (100MHz, DMSO) δ173.3,172.0,171.1,169.0,168.5,156.0,153.5,137.8,137.0,132.8,129.7,129.3,128.3 ,128.1,127.7,127.5,126.3,123.3,77.6,65.4,56.3,53.8,51.3,42.2,41.9,37.6,36.8,30.9,29.7,28.6,14.6
[0176] HRMS(ESI)m / z calcd.for C 39 H 50 N5O9S[M+H] + :764.3324,found:764.3330
[0177] Example 20
[0178] In this example, carfilzomib was prepared, and the specific process was as follows:
[0179] Dissolve chloroacetic acid (5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (5.5 mmol) in 5 mL of dichloromethane and stir at room temperature. Monitor the reaction progress by TLC. Once the starting acid is completely consumed, transfer the mixture to a pre-stirred mixture of L-homophenylalanine (10 mmol), N,O-bis(trimethylsilyl)acetamide (10 mmol), and dichloromethane (5 mL). Monitor the reaction progress by TLC. After the reaction, 20 mL of water was added, and the mixture was acidified to pH 2 with 1 M hydrochloric acid. The aqueous phase was extracted twice with ethyl acetate, and the organic phases were combined, washed once with water and once with saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The mixture was recrystallized with dichloromethane and diethyl ether, and the solid was collected by filtration to obtain a pure product. The above steps were repeated, and the product was condensed with L-phenylalanine, L-leucine, and (2S)-2-amino-4-methyl-1-[(2R)-2-methyloxiranyl]-1-pentanone trifluoroacetate in sequence. The resulting intermediate was reacted with morpholine (10 mmol), potassium iodide (KI, 5 mmol), and tetrahydrofuran (THF, 30 mL) in a reaction flask with stirring at room temperature under nitrogen protection, and the reaction was monitored by TLC and HPLC. After completion of the reaction, the reaction solution was concentrated, water and ethyl acetate were added, and the mixture was extracted three times with ethyl acetate. The organic phases were combined and dried over anhydrous magnesium sulfate. The reaction solution was concentrated and recrystallized from ethyl acetate and petroleum ether to obtain carfilzomib as a white solid in an overall yield of 65%. The following is the structural formula of the product and its nuclear magnetic resonance and mass spectrometry data:
[0180] 1 H NMR (400MHz, DMSO-d6) δ8.25(d,J=6.8Hz,1H),8.09(d,J=7.7Hz,1H),7.97(d,J=7.7Hz,1H),7.90(d,J=7.6Hz,1H), 7.33–7.23(m,2H),7.22–7.02(m,8H),4.61–4.49(m,1H),4.42–4.33(m,2H),4.32–4.23(m,1H),3.71–3.50(m,4H),3 .41–3.32(m,1H),3.12(d,J=4.2Hz,1H),3.05–2.85(m,4H),2.80–2.70(m,1H),2.57–2.51(m,1H),2.47–2.38(m,4H) ,1.93–1.76(m,2H),1.69–1.59(m,1H),1.55–1.47(m,1H),1.43–1.28(m,7H),0.89–0.83(m,6H),0.83–0.76(m,6H).
[0181] 13C NMR(100MHz,DMSO-d6)δ208.2,171.5,171.0,170.9,168.8,141.4,137.3,129.1,128.2,128.2,1 27.9,126.1,125.8,66.0,61.3,58.7,53.2,53.0,51.8,51.5,51.2,49.2,40.7,38.5,37.4,34.3, 31.4,24.5,24.1,23.2,23.0,21.6,21.0,16.3.
[0182] HRMS(ESI)m / z calcd.for C 40 H 58 N5O7[M+H] + :720.4331,found:720.4330.
[0183] Example 21
[0184] Octreotide was prepared in this example, and the specific process was as follows:
[0185] Boc-D-Phe-OH (5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (5.5 mmol) were dissolved in 20 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Cys(Trt)-OH (10 mmol), N,O-bistrimethylsilylacetamide (10 mmol), and dichloromethane (40 mL). The reaction progress was monitored by TLC. After the reaction was completed, 50 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain Boc-D-Phe-Cys(Trt)-OH. Repeat the above steps and condense with HD-Trp-OH, H-Lys(Boc)-OH, H-Thr(tBu)-OH, H-Cys(Trt)-OH, and L-threonine alcohol in sequence to obtain the protected octreotide linear Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr-ol. The intermediate was added to a reaction bottle pre-mixed with trifluoroacetic acid (42.5 mL), 1,2-ethanedithiol (2.5 mL), triisopropylsilane (2.5 mL) and water (2.5 mL). The mixture was stirred and the reaction was monitored by TLC and HPLC. After the reaction was completed, the linear octreotide was recrystallized from ether to obtain the linear octreotide. Finally, the linear octreotide was dissolved in water and diluted to a concentration of 10 -4 M was adjusted to pH 8 with 1 mmol of aqueous ammonia, and oxidized by bubbling air at room temperature for 48 hours. After freeze-drying, octreotide was obtained as a white solid in a total yield of 56%. The following is the structural formula of the product and the experimental data of nuclear magnetic resonance and mass spectrometry:
[0186] 1H NMR(400MHz,DMSO-d6)δ10.88(s,1H),9.04(d,J=8.2Hz,1H),8.70(d,J=4.5Hz, 1H),8.52(d,J=7.5Hz,1H),8.40(d,J=7.3Hz,1H),8.34(d,J=8.4Hz,1H),8.28–8.09(m,3H),7.98–7.85(m,3H),7.71(d,J=8.5Hz,1H),7.45(d,J=7.8Hz,1H),7.39–7.26(m,8H),7.21–7.18(m,2H),7.14–7.05(m,4H),7.02–6.97(m,2H),5.09(d,J=4.0Hz,1H),5.03–4.97(m,1H),4.90–4.84(m,1H),4.83–4.72(m,1H),4.64(s,1H),4.42(dd,J=8.4,5.4Hz,1H),4.24(dd,J=14.5,7.5Hz,2H),4.12–4.06(m,1H),4.00–3.92(m,2H),3.66–3.61(m,1H),3.18(dd,J=13.8,5.2Hz,1H),3.02–2.95(m,3H),2.92–2.72(m,7H),2.65–2.57(m,2H),1.73–1.64(m,1H),1.42–1.31(m,3H),1.11(d,J=6.2Hz,3H),1.05(d,J=6.4Hz,3H),0.89–0.77(m,2H).
[0187] 13 C NMR(100MHz,DMSO-d6)δ172.53,171.87,170.65,170.39,169.59,168.47,168.10,136.81,136.14,134.76,129.66,129.04,128.54,128.09,127.23,127.05,126.44,123.69,120.90,118.26,118.18,111.34,109.03,66.63,64.23,60.20,58.58,55.90,55.22,53.97,53.36,53.23,52.55,52.01,44.17,42.39,38.78,38.52,37.42,30.26,26.44,26.38,22.03,19.92,19.50.
[0188] HRMS(ESI)m / z calcd.for C 49 H 67 N 10 O 10 S2[M+H] + :1019.4478,found:1019.4484.
[0189] Example 22
[0190] This example prepares a protected lysine vasopressin linear chain, and the specific process is as follows:
[0191] Boc-Cys(Trt)-OH (5 mmol) and N-methyl-N-toluenesulfonyl acetylamine (5.5 mmol) were dissolved in 20 mL of dichloromethane and stirred at room temperature. The reaction progress was monitored by TLC. After the starting acid was completely consumed, the mixture was transferred to a pre-stirred mixture of H-Tyr(OtBu)-OH (10 mmol), N,O-bistrimethylsilylacetamide (10 mmol), and dichloromethane (40 mL). The reaction progress was monitored by TLC. After the reaction was completed, 50 mL of water was added and the mixture was acidified to pH 3 with 10% citric acid. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined and washed once with water and once with saturated brine. The organic phases were dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the mixture was recrystallized from dichloromethane and diethyl ether. The solid was collected by filtration to obtain Boc-Cys(Trt)-Tyr(OtBu)-OH. Repeat the above steps and sequentially condense with H-Phe-OH, H-Gln(Trt)-OH, H-Asn(Trt)-OH, H-Cys(Trt)-OH, H-Pro-OH, H-Lys(Boc)-OH, and H-Gly-NH2 to obtain the protected lysine vasopressin linear Boc-Cys(Trt)-Tyr(OtBu)-Phe-Gln(Trt)-Asn(Trt)-Cys(Trt)-Pro-Lys(Boc)-Gly-NH2 as a white solid in an overall yield of 55%. The following is the structural formula of the product and its nuclear magnetic resonance and mass spectrometry data:
[0192] 1H NMR(400MHz,DMSO-d6)δ8.67–8.60(m,1H),8.46–7.94(m,8H),7.65–7.54(m,2H),7.42–7.31(m,24H),7.24–6.96(m,43H),6.81–6.75(m,1H),6.73–6.46(m,3H),4.76–4.64(m,2H),4.53–4.43(m,2H),4.30–4.20(m,2H),4.15–4.07(m,1H),3.87–3.75(m,1H),3.69–3.59(m,2H),3.52–3.46(m,2H),3.17–3.05(m,2H),2.98–2.80(m,5H),2.77–2.65(m,3H),2.62–2.53(m,2H),2.46–2.33(m,4H),2.29–2.09(m,2H),2.04–1.89(m,2H),1.84–1.73(m,2H),1.66–1.57(m,2H),1.44–1.37(m,18H),1.34–1.28(m,4H),1.20(s,9H).
[0193] 13 C NMR(100MHz,DMSO-d6)δ171.81,171.77,171.57,171.34,171.15,170.85,170.76,170.66,169.27,168.60,168.18,155.57,154.83,153.24,144.92,144.71,144.31,144.26,137.67,132.03,129.86,129.84,129.19,129.11,129.07,128.58,128.55,128.07,127.99,127.46,127.44,126.70,126.31,126.14,123.24,78.53,77.39,69.42,69.26,66.45,65.85,59.31,53.74,53.14,52.93,52.01,50.90,49.79,46.42,41.98,37.43,37.33,33.93,32.72,32.46,31.30,31.24,29.30,29.24,29.17,28.56,28.32,28.15,24.25,22.69,22.63.
[0194] HRMS(ESI)m / z calcd.for C 136 H148 N 13 O 16 S2[M+H] + :2283.0603,found:2283.0610.
[0195] The present invention discloses a method for synthesizing amides and / or polypeptides using temporarily protected amino acids as ammonia components. The present invention uses alkynamide compounds as condensation reagents, uses low-cost unprotected amino acids as raw materials, and uses silanization agents to temporarily protect amino acids for condensation reaction, so that "protection-condensation-deprotection" is carried out in one pot, and the three-step reaction is combined into one step. After the construction of the peptide bond is achieved, the target polypeptide carboxylic acid can be obtained by simple acid treatment and directly used for the condensation of the next amino acid. At the same time, based on the characteristics of alkynamide condensation agents, this method can also completely avoid the generation of racemic by-products, ensuring the yield and purity of the product. This method saves a large amount of reagents and solvents used in the "protecting groups on amino acids" and "product deprotection" in traditional methods, reduces the generation of a large amount of chemical waste, greatly reduces the cost of polypeptide synthesis, and improves the atom economy and step economy of polypeptide synthesis.
[0196] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be considered as equivalent replacement methods and are included in the scope of protection of the present invention.
Claims
1. A method for preparing an amide and / or a polypeptide, characterized in that: The following steps are involved: After reacting the compound of formula I and the compound of formula II in solvent I, the compound of formula III, a silanization agent and solvent II are added to carry out a nucleophilic substitution reaction, and the compound of formula IV is obtained after acidification; Among them, R 1 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino acid residues lacking a C-terminal carboxyl group, amino acid derivative residues lacking a C-terminal carboxyl group, or polypeptide fragments; R 2 is selected from hydrogen, deuterium, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, silyl or alkylsilyl; R 3 is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R 4 is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino acid residue or polypeptide fragment; EWG is selected from nitro, cyano, sulfonyl, arylsulfonyl, alkanoyl, phosphonyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, silicon, alkylsilicon is optionally unsubstituted or replaced by one or more R 11 Replace; each R 11 Independently selected from halogen, hydroxy, carbonyl, C1-C6 alkyl.
2. The method for preparing an amide and / or polypeptide according to claim 1, characterized in that: When solvent II is different from solvent I, the method for preparing the amide and / or polypeptide further comprises removing the solvent I after the reaction and then performing the nucleophilic substitution reaction.
3. A method for preparing an amide and / or a polypeptide, characterized in that: The following steps are involved: The compound of formula V, the compound of formula III and the silanization agent are dissolved in solvent II to carry out a nucleophilic substitution reaction, and then acidified to obtain a compound of formula IV; Among them, R 1 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino acid residues lacking a C-terminal carboxyl group, amino acid derivative residues lacking a C-terminal carboxyl group, or polypeptide fragments; R 2 is selected from hydrogen, deuterium, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, silyl or alkylsilyl; R 3 is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R 4 is selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino acid residue or polypeptide fragment; EWG is selected from nitro, cyano, sulfonyl, arylsulfonyl, alkanoyl, phosphonyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, silicon, alkylsilicon is optionally unsubstituted or replaced by one or more R 11 Replace; each R 11 Independently selected from halogen, hydroxy, carbonyl, C1-C6 alkyl.
4. The method for preparing the amide and / or polypeptide according to claim 1 or 3, characterized in that: The silanization agent includes at least one of N-trimethylsilylacetamide, N-methyl-N-trimethylsilylacetamide, N-trimethylsilylpyrrolidone, N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide, N,O-bis(tert-butyldimethylsilyl)acetamide, N,O-bistrimethylsilylacetamide, N,O-bis(trimethylsilyl)trifluoroacetamide, N-methyl-N-(trimethylsilyl)trifluoroacetamide, hexamethyldisilazane, trimethylsilylimidazole, dimethyldichlorosilane, trimethylchlorosilane and tert-butyldimethylchlorosilane.
5. The method for preparing the amide and / or polypeptide according to claim 1 or 3, characterized in that: The molar ratio of the silanization agent to the compound of formula III is (0.5-20):
1.
6. The method for preparing the amide and / or polypeptide according to claim 1 or 3, characterized in that: The solvent I includes at least one of dichloromethane, chloroform, 1,2-dichloroethane, ether, toluene, acetonitrile, methanol or ethanol; preferably, the solvent II includes at least one of acetonitrile, ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, dioxane, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, toluene, m-xylene, dichloromethane, 1,2-dichloroethane or chloroform.
7. The method for preparing the amide and / or polypeptide according to claim 1 or 3, characterized in that: The temperature of the nucleophilic substitution reaction is -20°C to 150°C.
8. The method for preparing the amide and / or polypeptide according to claim 1 or 3, characterized in that: The compound of formula III includes any one of amino acid compounds, polypeptide compounds with free amino and carboxyl groups, or other compounds having both amino and carboxyl groups.
9. The method for preparing an amide and / or polypeptide according to claim 3, characterized in that: The method for preparing the amide and / or polypeptide comprises the following steps: dissolving the compound of formula III and a silanization agent in a solvent II, adding the compound of formula V to carry out a nucleophilic substitution reaction, and obtaining the compound of formula IV after acidification.
10. The method for preparing an amide and / or polypeptide according to claim 3, characterized in that: The preparation method of the compound of formula V comprises the following steps: The compound of formula I and the compound of formula II are dissolved in solvent I, and stirred to react to obtain a compound of formula V; Among them, R 1 , R 2 , R 3 , the definition of EWG is as described in claim 1.
11. The method for preparing an amide and / or polypeptide according to claim 1 or 3, characterized in that: The method for preparing the amide and / or polypeptide comprises the following steps: S1: dissolving the compound of formula I and the compound of formula II in solvent I, stirring and reacting to obtain a compound of formula V; S2: dissolving the compound of formula V, the compound of formula III, and a silanization agent in solvent II to carry out a nucleophilic substitution reaction, and then acidifying to obtain a compound of formula IV; Among them, R 1 , R 2 , R 3 , R 4 , the definition of EWG is as described in claim 1 or 3.
12. The method for preparing an amide and / or polypeptide according to claim 11, characterized in that: The compound of formula I comprises at least one of fatty acids, aromatic acids, heterocyclic acids, acetylenic acids, olefinic acids, amino acids, polypeptide carboxylic acids and derivatives of the above compounds.
13. The method for preparing an amide and / or polypeptide according to claim 11, characterized in that: The molar ratio of the compound of formula I to the compound of formula III is 1:(0.1-5).
14. Use of the method for preparing an amide and / or a polypeptide according to any one of claims 1 to 13 in preparing an amide and / or a polypeptide.
Citation Information
Patent Citations
Mild and efficient preparation method of alpha-acyloxy alkenyl amide compound and application thereof to synthesis of amide and polypeptide
CN106146359A
Method for preparing carfilzomib by using water-soluble alkyne amide as condensing agent
CN113024637A
Alpha-carbonyl alkenyl ester compound as well as preparation method and application thereof
CN113292430A
Synthesis method of pasireotide intermediate
CN113845569A
Method for producing peptide compound
WO2019069978A1
